Mounjaro weight loss results: what the before and after pictures actually show

What SURMOUNT-1 actually measured, and why the numbers matter more than photos

The SURMOUNT-1 trial is the primary evidence base for Mounjaro's weight-loss results. Over 72 weeks, adults with obesity (no type 2 diabetes) who received tirzepatide 15mg lost an average of around 20–21% of their starting body weight. Some analyses put the figure closer to 22.5% in the group that completed treatment as planned. To put that in concrete terms: someone starting at 100kg could, on average, expect to lose 20kg or more. That is the population average from a large, rigorously controlled study, it is not a guarantee for any individual. The NHS medicines page for tirzepatide summarises the medicine's evidence and licensed uses in plain English.

Before and after photographs, by contrast, tend to be self-selected. People who experienced dramatic results are more likely to share them; people whose outcomes were more modest are less visible. This is not criticism of those sharing their stories, it is simply how image-based content works. If you want to see what that distribution looks like in practice, our collection of Mounjaro before and after pictures draws from a range of starting points rather than only the most striking outcomes. The trial data gives you the honest distribution; a photograph gives you one data point from the favourable end of it.

One further detail worth understanding: SURMOUNT-1 results were measured at the 15mg maintenance dose, which most participants only reached after a slow titration over several months. The starter dose (2.5mg) is there to let the body adjust, not to produce the headline weight-loss figure. If you want a clearer sense of how long Mounjaro takes to work at each stage, that context matters enormously.

How tirzepatide produces the results behind those before and after comparisons

Mounjaro activates two gut-hormone receptors simultaneously (GIP and GLP-1) making it the only dual-agonist weight-loss medicine licensed in the UK. Both pathways are involved in appetite regulation and blood-sugar control; together they slow gastric emptying and increase feelings of fullness after eating. Most people find they feel full on noticeably smaller portions, and the urge to snack between meals diminishes. Over weeks and months, a sustained reduction in calorie intake drives the weight loss that later appears in before and after comparisons.

This mechanism also explains why results build gradually. The first pen's job is largely adjustment, the dose is low, and the priority is tolerability. The results in those comparison photographs typically reflect six months or more of treatment at a maintained dose, alongside consistent dietary change. Mounjaro is not a fast-acting stimulant; the biology is slow and cumulative. Many people keep their pen in the fridge next to everyday items and inject once a week without the process feeling dramatic, yet the cumulative effect over a year is what those images ultimately capture. For a fuller picture of what that progress looks like across different timeframes, our page on Mounjaro results before and after sets out what the evidence suggests you can reasonably expect at each stage.

For a deeper look at the evidence behind tirzepatide, the full Mounjaro overview covers mechanism, licensed use and trial results in detail.

Eligibility, variation and what before and after pictures cannot tell you

Mounjaro is licensed in the UK for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as hypertension, type 2 diabetes, high cholesterol or obstructive sleep apnoea. NICE's appraisal of tirzepatide (TA1026) recommends it for NHS use in adults with a BMI of 35 or above and at least one weight-related comorbidity, with lower BMI thresholds applying for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. Private treatment has a broader entry point, but a prescriber still assesses the full picture, not just BMI.

What the photographs circulating online rarely show is the starting health profile of the person in them: their exact BMI, what comorbidities they had, whether they made significant dietary changes, how they tolerated the titration schedule, or what dose they ultimately reached. All of these variables shape outcomes. The trial data captures this spread honestly, some participants lost under 10% of body weight, others over 25%. Before and after pictures, almost by definition, show the outcomes people were most motivated to share.

If you're curious about how results compare across different populations and treatment lengths, the tirzepatide weight loss results page explores that evidence in more depth. And for context on how Mounjaro compares to semaglutide in head-to-head data, this results comparison covers the SURMOUNT-5 findings directly.

One honest note on cost: people sometimes encounter images and then immediately search for the cheapest way to access Mounjaro. A brief read of the treatment overview is worth the few minutes, it explains the private prescription process and what a legitimate service includes. For specific questions about what's involved at each stage, our FAQs cover the most common ones.

If you've reviewed the evidence and want to find out whether Mounjaro is clinically suitable for you, the place to start is a proper assessment. At nume, every consultation is read by a GPhC-registered prescriber (a real clinician, not automated software) on the day you submit it. Start your free consultation and get a clear answer based on your individual health profile.